Inhibitory effect of novel 1-deoxynojirimycin derivatives on HIV-1 replication.
The effect of 11 derivatives of 1-deoxynojirimycin (DNM) on the replication of HIV-1 was studied. Compared with DNM, seven of them showed remarkable inhibition of HIV-1-induced syncytium formation at significantly low concentrations which were not cytotoxic. Two derivatives were found to markedly reduce the infectious virus yields from cell lines chronically infected with HIV. Analysis of HIV-1 envelope glycoproteins showed that the derivatives induced modification of the processing of not only gp120/160 but also the transmembrane glycoprotein gp41. The modification of the processing of the transmembrane glycoprotein gp41 might play an important role in the inhibition of virus replication at a step after the binding of gp120 to CD4. The enhanced anti-HIV activity of DNM derivatives reported here could increase the possibility of non-toxic therapeutic intervention in HIV infections.
Shimizu
H
H
AIDS Research Center, National Institute of Health, Musashimurayama, Tokyo, Japan.
Tsuchie
H
H
Yoshida
K
K
Morikawa
S
S
Tsuruoka
T
T
Yamamoto
H
H
Ushijima
H
H
Kitamura
T
T
D017485:1-Deoxynojirimycin; D015153:Blotting, Western; D002460:Cell Line; D015726:Giant Cells / Q000187:drug effects; D005944:Glucosamine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015700:HIV Envelope Protein gp41 / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D017485:1-Deoxynojirimycin; D005944:Glucosamine